A Phase 2 interventional study of Pregabalin and Acetaminophen in Postoperative Pain, sponsored by Nevakar, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-23.
Sponsored by Nevakar, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.
Among the 65 studies testing pregabalin in Pain, Postoperative, this one is the 38th largest by enrollment, is one of 5 that started in 2020, is one of 4 in phase 2, and was the 50th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Tanta University · Sites in Egypt
Ages 21–60
Bahrain Defence Force Hospital · Sites in Bahrain
Ages 18–85
Medical University of Warsaw · Sites in Poland
Ages 18+
Ain Shams University · Sites in Egypt
Ages 21–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 20 · Phase 4 21
First in 2005; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 65 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 65 have an industry lead sponsor. The 10 most frequent:
Nevakar, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Nevakar, Inc. has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing pregabalin in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05150795Ain Shams UniversityEffect of Preoperative Oral Pregabalin Versus Intraoperative Fentanyl on Postoperative Analgesia | 2026-12 |
| NCT07344467Tanta UniversityOral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing pregabalin in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy
A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy
Up to 80 subjects will be randomized (32 in each active treatment group, 16 placebo).
To evaluate the efficacy of combination pregabalin (PGB) and acetaminophen (APAP) administered vs. placebo for pain control in subjects undergoing bunionectomy.
The placebo will be the saline solution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have a medical condition or history that in the Investigator's opinion could adversely impact the subject's participation or safety or the conduct of the study, or interfere with the pain assessments, including the following:
Known bleeding disorder or is taking agents affecting coagulation preoperatively.
Deep venous thrombosis (DVT) prophylaxis of the surgeon's choice is permitted postoperatively.
Use of disallowed medications including the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
Drug: Pregabalin · Drug: Acetaminophen
Group B receives placebo 2 prior to surgery and APAP post-surgery.
Drug: Acetaminophen · Other: Placebo 2
Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
Other: Placebo 1 · Other: Placebo 2
Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
Also known as: PGB
Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Also known as: APAP
Placebo for APAP
Placebo for combination
Summed Pain Intensity (SPI) Between Group A and Group C
Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, was used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: Sum (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and placebo (Group C) from Hour 0 to Hour 48 (SPI0-48)
Time frame: 0 to 48 hours
Summed Pain Intensity (SPI) Compared Between Group A and Group B
Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) -was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and APAP alone (Group B) from Hour 0 to Hour 48 (SPI0-48)
Time frame: 0 to 48 hours
Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale From Hour 0 to Hour 12 (SPI0-12), Hour 12 to Hour 24 (SPI12-24), and Hour 24 to Hour 48 (SPI24-48).
Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals at 0-12, 12-24 and 24-48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time interval (0-12, 12-24 and 24-48 hours). This outcome was compared between a combination of PGB and APAP, APAP alone, and placebo.
Time frame: 0, 12, 24, 48 hours
Summed Pain Intensity (SPI) Assessed by Numeric Rating Scale Over Time
Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals from 0 hour till each time point at 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time intervals.
Time frame: 0, 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours
Number of Participants With Treatment-Related Adverse Events (TRAE)
A TRAE is defined as a treatment-emergent adverse event (TEAE) that was classified by the investigator as related to study drug. The number of participants with TRAE were reported
Time frame: 7 days
Percentage of Participants Who Were Opioid Free Over Time
Percentages of participants who did not take opioid (rescue medication) over time.
Time frame: 12 to 48 hours
Total Consumption of Opioid Rescue Medication Through 24 Hours and 48 Hours
The total consumption of opioid rescue analgesia through 24 hours and through 48 hours was reported
Time frame: 24 hours and 48 hours
Total Consumption of Rescue Medication
The total consumption of rescue analgesia was reported.
Time frame: 7 days
Time to First Use of Rescue Medication From Hour 0
Time to first use of rescue medication from Hour 0 was reported. Hour 0 was defined as the end of surgery (i.e., completion of the last suture).
Time frame: 7 days
Percentage of Participants Who Used Rescue Medication
Percentage of participants who used rescue medication is reported
Time frame: 7 days
Patient Global Assessment of Pain
Patient Global Assessment (PGA) of pain control at 48 hours was reported. Patient global evaluation will be self-reported over 24 hours, using a 0-4 categorical rating scale of: (0) poor, (1) fair, (2) good, (3) very good, and (4) excellent
Time frame: 48 hours
Maximum Observed Concentration for PGB and APAP
The Plasma Concentration (Cmax) is defined as the maximum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.
Time frame: Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion
Minimum Observed Concentration for PGB and APAP
The Plasma Concentration (Cmin) is defined as the minimum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.
Time frame: Pre-infusion (at least 3.0 minutes before the start of the first infusion) and at 0.5, 1.5, 6.0, 8.0, 12.0, 16.0, 18.0, 24.0, 30.0, 32.0, 36.0, 40.0, 42.0, and 48 hours post-infusion
Participants were recruited from 28 July 2020 till 26 Oct 2020 across the sites.
| Milestone | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Started | 35 | 35 | 17 |
| Completed | 34 | 34 | 14 |
| Not completed | 1 | 1 | 3 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 1 |
Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, was used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: Sum (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and placebo (Group C) from Hour 0 to Hour 48 (SPI0-48)
| score on a scale | PGB and APAP (Group A) | Placebo (Group C). |
|---|---|---|
| Summed Pain Intensity (SPI) Between Group A and Group C | 153.08 ± 15.238 | 267.51 ± 21.864 |
Pain Intensity using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with a score between 0-10 (0= no pain; 10 = worst imaginable pain). Summed Pain Intensity (SPI0-48) -was calculated using the trapezoidal method as the area under the curve (AUC) of pain intensity as measured using the NRS through various time intervals up to 48 hours. For SPI0-48 calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) from 0 to 48 hours, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI0-48 was calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at various time points. This outcome was compared between a combination of PGB and APAP (Group A) and APAP alone (Group B) from Hour 0 to Hour 48 (SPI0-48)
| score on a scale | PGB and APAP (Group A) | APAP (Group B) |
|---|---|---|
| Summed Pain Intensity (SPI) Compared Between Group A and Group B | 153.08 ± 15.238 | 223.24 ± 5.238 |
Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals at 0-12, 12-24 and 24-48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time interval (0-12, 12-24 and 24-48 hours). This outcome was compared between a combination of PGB and APAP, APAP alone, and placebo.
| score on a scale | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| SPI 0-12 | 33.09 ± 3.728 | 49.09 ± 3.728 | 58.89 ± 5.349 |
| SPI 12-24 | 50.92 ± 5.082 | 69.35 ± 5.082 | 88.95 ± 7.292 |
| SPI 24-48 | 126.83 ± 13.128 | 184.33 ± 13.128 | 221.58 ± 18.837 |
Pain Intensity was determined using a pain rating of 0-10 on the NRS, with a score between 0-10 (0= no pain; 10 = worst imaginable pain). SPI were calculated using the trapezoidal method as the AUC of pain intensity as measured using the NRS through various time intervals from 0 hour till each time point at 1, 2, 4, 6, 8, 10 ,12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, and 48 hours. For specific time interval SPI calculation, all available NRS pain intensity scores (scheduled pain intensity, unscheduled pain intensity and pre-rescue pain intensity) in the respective time interval, including any imputed values, were used in the calculation. Hour 0 was defined as the time of the end of surgery. SPI at various time intervals were calculated using the formula: SUM (1/2 (SPIi + SPIi+1)\*Δt), where Δt was the time difference between Time i and Time (i+1). The represented values are sum of pain intensity scores at respective time intervals.
| score on a scale | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| SPI 0-1 | 0.26 ± 0.509 | 0.73 ± 0.870 | 0.45 ± 0.951 |
| SPI 0-2 | 1.26 ± 1.591 | 2.39 ± 2.539 | 2.16 ± 2.560 |
| SPI 0-4 | 5.63 ± 5.120 | 8.02 ± 6.703 | 9.62 ± 6.196 |
| SPI 0-6 | 12.68 ± 9.650 | 17.09 ± 10.606 | 20.71 ± 10.368 |
| SPI 0-8 | 20.00 ± 14.211 | 28.09 ± 14.266 | 33.64 ± 14.203 |
| SPI 0-10 | 26.25 ± 18.413 | 38.71 ± 18.140 | 45.95 ± 18.510 |
| SPI 0-12 | 33.09 ± 22.725 | 49.09 ± 21.692 | 58.89 ± 21.362 |
| SPI 0-14 | 41.12 ± 27.035 | 58.62 ± 25.009 | 72.17 ± 24.820 |
| SPI 0-16 | 49.08 ± 30.480 | 67.98 ± 27.401 | 84.46 ± 27.487 |
| SPI 0-18 | 55.84 ± 33.985 | 78.49 ± 31.847 | 97.57 ± 32.420 |
| SPI 0-20 | 61.49 ± 36.259 | 86.24 ± 35.453 | 108.32 ± 37.011 |
| SPI 0-24 | 77.17 ± 43.864 | 108.25 ± 43.928 | 134.91 ± 42.035 |
| SPI 0-28 | 88.94 ± 50.680 | 128.83 ± 52.561 | 158.01 ± 45.579 |
| SPI 0-32 | 100.85 ± 56.483 | 148.93 ± 59.923 | 180.50 ± 54.648 |
| SPI 0-36 | 114.43 ± 63.776 | 169.44 ± 67.178 | 203.32 ± 64.342 |
| SPI 0-40 | 126.45 ± 69.998 | 186.70 ± 73.308 | 224.78 ± 72.951 |
| SPI 0-44 | 139.54 ± 78.396 | 199.95 ± 78.945 | 246.09 ± 84.178 |
| SPI 0-48 | 153.08 ± 87.398 | 223.24 ± 91.581 | 267.51 ± 92.791 |
A TRAE is defined as a treatment-emergent adverse event (TEAE) that was classified by the investigator as related to study drug. The number of participants with TRAE were reported
| participants | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Number of Participants With Treatment-Related Adverse Events (TRAE) | 22 | 9 | 7 |
Percentages of participants who did not take opioid (rescue medication) over time.
| percentage of participants | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| During 12-24 Hours | 65.7 | 45.7 | 35.3 |
| During 12-48 Hours | 48.6 | 28.6 | 29.4 |
The total consumption of opioid rescue analgesia through 24 hours and through 48 hours was reported
| oral morphine equivalents | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Consumption of Rescue Medication through 24 hours | 9.86 ± 14.134 | 19.24 ± 17.019 | 28.88 ± 20.981 |
| Consumption of Rescue Medication through 48 hours | 17.36 ± 21.796 | 33.39 ± 30.847 | 43.88 ± 32.419 |
The total consumption of rescue analgesia was reported.
| oral morphine equivalents | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Total Consumption of Rescue Medication | 17.79 ± 22.344 | 34.24 ± 32.496 | 44.76 ± 33.609 |
Time to first use of rescue medication from Hour 0 was reported. Hour 0 was defined as the end of surgery (i.e., completion of the last suture).
| hours | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Time to First Use of Rescue Medication From Hour 0 | 11.60 (5.93 to 16.12) | 5.78 (4.27 to 7.97) | 4.31 (3.57 to 5.87) |
Percentage of participants who used rescue medication is reported
| percentage of participants | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Percentage of Participants Who Used Rescue Medication | 57.1 | 80.0 | 82.4 |
Patient Global Assessment (PGA) of pain control at 48 hours was reported. Patient global evaluation will be self-reported over 24 hours, using a 0-4 categorical rating scale of: (0) poor, (1) fair, (2) good, (3) very good, and (4) excellent
| Participants | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| (0) Poor | 1 | 1 | 1 |
| (1) Fair | 4 | 7 | 7 |
| (2) Good | 6 | 7 | 3 |
| (3) Very good | 10 | 10 | 3 |
| (4) Excellent | 14 | 9 | 1 |
The Plasma Concentration (Cmax) is defined as the maximum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.
| nanogram per milliliter (ng/ml) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Mean Cmax Values of Pregabalin- First Dose | 10068 ± 36 | — | — |
| Mean Cmax Values of Pregabalin- Last Dose | 12960 ± 27 | — | — |
| Mean Cmax Values of Acetaminophen-First Dose | 28700 ± 34 | 16847 ± 39 | — |
The Plasma Concentration (Cmin) is defined as the minimum observed concentration. Multiple blood samples were drawn at pre-decided time points. Timing for blood draws was within 3 minutes of the end of every infusion. Three minutes was the maximum allowance as every effort was made to take the sample as close as possible to 1.0 minute after infusion.
| nanogram per milliliter (ng/ml) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| Minimum Observed Concentration for PGB and APAP | NA ± NA | NA ± NA | — |
Collected over Up to 7 days (± 1 day). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PGB and APAP (Group A) | 0/35 (0%) | 0/35 (0%) | 27/35 (77.1%) |
| APAP (Group B) | 0/35 (0%) | 0/35 (0%) | 15/35 (42.9%) |
| Placebo (Group C). | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Event | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). |
|---|---|---|---|
| DizzinessNervous system disorders | 18/35 | 3/35 | 3/17 |
| NauseaGastrointestinal disorders | 9/35 | 5/35 | 5/17 |
| VomitingGastrointestinal disorders | 5/35 | 2/35 | 4/17 |
| HeadacheNervous system disorders | 3/35 | 2/35 | 2/17 |
| Application site rashGeneral disorders | 0/35 | 0/35 | 1/17 |
| Injection site extravasationGeneral disorders | 2/35 | 0/35 | 1/17 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/35 | 0/35 | 1/17 |
| BlisterSkin and subcutaneous tissue disorders | 0/35 | 0/35 | 1/17 |
| Transaminases increasedInvestigations | 2/35 | 2/35 | 0/17 |
| TachycardiaCardiac disorders | 0/35 | 1/35 | 0/17 |
The Safety Analysis Set included all subjects who received any amount of study drug (APAP + PGB, APAP, or placebo), whether or not they were prematurely withdrawn from the study.
| Age, Continuous(years) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). | Total |
|---|---|---|---|---|
| Mean | 43.7 ± 13.33 | 42.1 ± 11.68 | 43.3 ± 11.98 | 43.0 ± 12.31 |
| Sex: Female, Male(Participants) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). | Total |
|---|---|---|---|---|
| Female | 25 | 31 | 17 | 73 |
| Male | 10 | 4 | 0 | 14 |
| Ethnicity (NIH/OMB)(Participants) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 12 | 7 | 28 |
| Not Hispanic or Latino | 26 | 23 | 10 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 1 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 7 | 4 | 18 |
| White | 24 | 26 | 12 | 62 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Mass Index(kg/m^2) | PGB and APAP (Group A) | APAP (Group B) | Placebo (Group C). | Total |
|---|---|---|---|---|
| Mean | 26.03 ± 3.213 | 26.55 ± 3.471 | 26.05 ± 3.406 | 26.24 ± 3.326 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Nov 2020, 3 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Acetaminophen
Nevakar, Inc.